Safety and pharmacokinetics of ralinepag, a novel oral prostacyclin receptor agonist
Ralinepag XR has a half-life suitable for once-daily dosing. The reduced C<sub>max</sub> and delayed T<sub>max</sub> contributes to lower peak-to-trough fluctuations and may provide favorable effects for sustained efficacy and improved tolerability.
Authors
- Ali Ataya (ORCID: https://orcid.org/0000-0001-8505-1680)
- Murali M. Chakinala (ORCID: https://orcid.org/0000-0002-3782-341X)
- M. Patricia George (ORCID: https://orcid.org/0000-0002-6534-1020)
- Scott Seaman (ORCID: https://orcid.org/0000-0002-1732-7160)
- Meredith Broderick (ORCID: https://orcid.org/0000-0002-1871-1615)
- James C. Coons (ORCID: https://orcid.org/0000-0002-7193-3751)
- Namita Sood
- Natalie Patzlaff
Institutions
- University of Pittsburgh (US)
- Washington University in St. Louis (US)
- National Jewish Health (US)
- University of Florida (US)
- United Therapeutics (United States) (US)
- Jewish Hospital (US)
- University of California, Davis (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- JHLT Open
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1016/j.jhlto.2025.100270
- Citations
- 1
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- United Therapeutics Corporation